IRB granted patent for GPI derivatives in US market
Italian Biotechnology company IRB has been granted a patent in the US for its Glycerophosphoinositol (GPI) derivatives.
The ingredients can be used as modulators of Cytosolic A Phospholipase, acting as an active ingredient with a broad spectrum of applications for control of cPLA2 activity, making it appropriate for dermatological conditions such as dermatitis.
The company says that the GPI derivatives have demonstrated clear anti-inflammatory properties, as well as helping to offset irritations such as itching without any associated side effects.
“This opens a number of opportunities for our customers operating in the US, giving intellectual property coverage to several GPI derivatives and to a number of potential uses both in cosmetic and pharmaceutical areas,” said Elena Sgaravatti, general manager at IRB.
